Biochanine A

Nom de la substance

Potentialités dans le traitement de l'ostéoporose post-ménopausique ^[1], ^[2], ^[3]
Potentialités dans le traitement de la maladie de Legg-Calvé-Perthes (ou ostéochondrite primitive de la hanche, entrainant une ostéonécrose de la tête fémorale), en raison de ses effets sur la dysfonction endothéliale, prédits par les études de pharmacologie en réseau ^[4]

↑ Inpan R, Na Takuathung M, Sakuludomkan W, Dukaew N, Teekachunhatean S, Koonrungsesomboon N. Isoflavone intervention and its impact on bone mineral density in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Osteoporos Int. 2024 Mar;35(3):413-430. doi: 10.1007/s00198-023-06944-y. Epub 2023 Oct 25. PMID 37875614.
↑ Kumari S, Singh M, Nupur, Jain S, Verma N, Malik S, Rustagi S, Priya K. A review on therapeutic mechanism of medicinal plants against osteoporosis: effects of phytoconstituents. Mol Biol Rep. 2023 Nov;50(11):9453-9468. doi: 10.1007/s11033-023-08751-4. Epub 2023 Sep 7. PMID 37676432.
↑ He Q, Yang J, Chen W, Pan Z, Chen B, Zeng J, Zhang N, Lin Y, Chen C, Xiao J, Li M, Li S, Wang H, Chen P. Biochanin A abrogates osteoclastogenesis in type 2 diabetic osteoporosis via regulating ROS/MAPK signaling pathway based on integrating molecular docking and experimental validation. BMC Complement Med Ther. 2024 Jan 8;24(1):24. doi: 10.1186/s12906-023-04332-x. PMID 38191438; PMCID: PMC10773052.
↑ Liu J, Hua Z, Liao S, Li B, Tang S, Huang Q, Wei Z, Lu R, Lin C, Ding X. Prediction of the active compounds and mechanism of Biochanin A in the treatment of Legg-Calvé-Perthes disease based on network pharmacology and molecular docking. BMC Complement Med Ther. 2024 Jan 9;24(1):26. doi: 10.1186/s12906-023-04298-w. PMID 38195507; PMCID: PMC10775507.